Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2021	$ 38	$ 442,259	$ (138)	$ (347,104)	$ 95,055
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	37,918,395
Exercises of vested stock options		12			12
Exercises of vested stock options (in shares)	11,484
Vesting of restricted stock units (in shares)	312,090
Stock based compensation expense		2,268			2,268
Net unrealized gain (loss) on available-for-sale securities			(85)		(85)
Net income (loss)				(21,319)	(21,319)
Stockholders' Equity, Ending Balance at Mar. 31, 2022	$ 38	444,539	(223)	(368,423)	75,931
Shares, Outstanding, Ending Balance at Mar. 31, 2022	38,241,969
Stockholders' Equity, Beginning Balance at Dec. 31, 2022	$ 38	452,713	(219)	(393,512)	59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022	38,613,891
Exercises of vested stock options		185			$ 185
Exercises of vested stock options (in shares)	51,993				51,993
Vesting of restricted stock units (in shares)	374,417
Issuance of common stock in connection with Neurocrine Collaboration Agreement	$ 5	31,116			$ 31,121
Issuance of common stock in connection with Neurocrine Collaboration Agreement (in shares)	4,395,588
Stock based compensation expense		2,504			2,504
Net unrealized gain (loss) on available-for-sale securities			87		87
Net income (loss)				124,044	124,044
Stockholders' Equity, Ending Balance at Mar. 31, 2023	$ 43	$ 486,518	$ (132)	$ (269,468)	$ 216,961
Shares, Outstanding, Ending Balance at Mar. 31, 2023	43,435,889